Bio-Techne management check

TECH · Health Care · Life Sciences Tools & Services · CEO Kim Kelderman

Filings as of

45
Management score, ranked 453rd of 487 · 56th of 60 in Health Care2 good · 3 to watch · 2 flaggedStrongest: pay for performance · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$79Peers$104

    What $100 became since fiscal 2021

    2130th
    Detail

    $100 invested at the start of fiscal 2021 grew to $79, against $104 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9067th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.79 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Flag

    What does the CEO cost owners?

    11.1% of net income

    $8.2m pay · $73.4m net income, FY2025

    0.1%1%3%10%
    016th
    Detail

    $8.2m of reported pay in fiscal 2025, against $73.4m of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 0.7 years of pay

    80,509 shares ≈ $5.8m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $0 sold

    2826th
    Detail

    The CEO holds 80,509 shares, directly or through trusts (unvested awards not counted): about 0.7 years of pay. No open-market insider buying or selling in the last six months.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 162m2025 · 160m

    Diluted shares −0.7% a year; flagged above +2%

    0%10%20%

    Stock pay 3.3% of revenue

    5848th
    Detail

    Diluted shares changed -0.7% a year over the last three fiscal years. Stock-based pay was 3.3% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    7 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Mr. Kummeth, Mr. Kelderman

    5025th
    Detail

    CEOs in the pay table: Mr. Kummeth, Mr. Kelderman. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Watch

    Are the books clean?

    An annual report was amended

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 110-K amended
    7015th
    Detail

    No restatements, auditor changes or late filings since 2021. 1 amended annual report.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed September 19, 2025.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$52.8m$105.7m$10020212022202320242025$79$104

Pay tied most to organic revenue

Other key measuresOrganic RevenueAdjusted Net Income

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Kelderman$8.2m$2.5m$3.7m$79$104$73.4m
2024Mr. Kelderman, Mr. Kummeth$6.8m$4.8m$3.3m$110$131$168.1m
2023Mr. Kummeth$30.6m$4.7m$2.3m$125$127$285.4m
2022Mr. Kummeth$15.4m$0$3.2m$132$130$263.1m
2021Mr. Kummeth$15.9m$105.7m$5.0m$171$148$139.6m

Insiders and the CEO's stakeQuiet

Chief Executive Officer
Kim Kelderman
Shares held
80,509
At that filing's price
≈ $5.8m
Latest Form 4
Nov 1, 2026

No open-market insider buying or selling in the last six months.

Open-market trades by officers and directors since May 21, 2026.

Leadership and governance on file

20222023202420252026Leadership 11Red flags 1Votes 5
All 12 filings

Latest shareholder vote results: Sep 23, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $830.4m returned to owners in buybacks and dividends, 88% of net income, and $209.3m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$163.1m$326.1m20212022202320242025Shares162m164m162m161m160m
Show the figures
Fiscal year20212022202320242025
Revenue$931.0m$1.1bn$1.1bn$1.2bn$1.2bn
Net income$140.4m$272.1m$285.3m$168.1m$73.4m
Stock-based pay$49.0m$42.2m$39.2m$38.0m$40.8m
Buybacks$43.2m$160.9m$19.6m$80.0m$275.7m
Dividends$49.6m$50.2m$50.3m$50.4m$50.4m
Diluted shares162m164m162m161m160m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.